109 Results
Sort By:
Published on October 5, 2022
Researchers from the University of California Los Angeles have developed a novel assay that can overcome the challenges of detecting cell-free (cf)DNA as an early indicator of cancer in a cost-effective way. Cell-free DNA describes small, freely floating DNA fragments in the bloodstream that, in the context of cancer, have…
Published on October 22, 2021
Scientists at St. Jude Children’s Research Hospital have demonstrated that cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) can be used to detect measurable residual disease (MRD) in children treated for medulloblastoma. The researchers developed a test to detect MRD, and thus the risk of relapse, earlier than a recurrent tumor…
Published on April 7, 2021
A new nanopore sensing technique, using a tiny glass tube and electric current, developed by scientists from the University of California-Riverside could provide a better way to capture DNA from fluid samples such as blood and improve cancer diagnosis in the future. The technique was described recently in the paper…
Published on January 14, 2021
Researchers have developed a blood test to detect acute heart transplant rejection, a potentially deadly condition that occurs in the early months after a patient has received a donor heart. Typically, these patients must undergo endomyocardial biopsy (EMBx) to monitor for acute rejection. But EMBx is an invasive procedure and…
Published on April 1, 2020
A study of a new blood test detected more than 50 types of cancer, along with their location in the body, with a high degree of accuracy. The test analyzes the arrangement of methyl groups on circulating cell-free DNA (cfDNA) released from cancer cells. In cancer cells, the placement of…
Published on January 6, 2020
AMS Biotechnology has announced the launch of its updated cfPure Cell Free DNA Purification Kit for scalable and automation-friendly isolation of circulating cell-free DNA (cfDNA) from patient serum or plasma samples. The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from…
Published on October 24, 2019
The blood-based cell-free DNA (cfDNA) HELIXAFE test can detect solid tumors even before they develop, according to a study published in the journal Cell Death & Disease by an international group of experts coordinated by Bioscience Genomics, a research entity formed by the collaboration between the University of Rome Tor Vergata and Bioscience…
Published on July 17, 2018
There will be roughly 1.7 million new cases of cancer diagnosed in the United States this year. For each one, the earlier the diagnosis the better. Although some cancers have routine screening methods such as colon cancer, multiple barriers prevent one-third of eligible people from being screened. For many cancers,…
Published on March 29, 2018
Freenome’s artificial intelligence (AI) genomics platform will be evaluated by Institut Curie as a novel tool to predict patient response to immuno-oncology therapies, the partners said today, through a collaboration whose value was not disclosed. Freenome’s Adaptive Genomics Engine platform will be evaluated by observing changes in circulating cell-free biomarkers,…
Published on January 24, 2018
Sponsor: SYGNIS TruePrime is an apoptotic cell-free DNA amplification kit, launched under the Expedeon brand, which enables accurate DNA amplification using cell-free DNA (cfDNA) obtained from plasma, serum, urine, cerebrospinal fluid (CSF), or many other bodily fluids. The TruePrime kit uses a novel multiple displacement amplification method to overcome common…
Published on May 26, 2017
SomaGenics, a 20-year-old spinoff of nonprofit research organization SRI International has received a Phase 1 grant from the National Human Genome Research Institute (NHGRI), to develop a cell-free DNA (cfDNA) liquid biopsy platform, a tool for researchers to analyze and log single-stranded DNA fragments less than 100 nucleotides long. The…
Published on January 17, 2024
Researchers from Dana-Farber Cancer Institute and the University of Trento, Italy, report in Cancer Discovery, that they have developed a new blood test differentiates neuroendocrine prostate cancer (NEPC) once it has advanced from adenocarcinoma. Having a non-invasive method to detect this switch has important implications for this hard-to-treat form of…
Published on January 10, 2024
Veracyte announced it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) testing capabilities from cell-free DNA (cfDNA) in liquid biopsies. C2i’s MRD solution requires less than a tube of blood (as little as 3–4 mL blood or 1–2…
Published on November 13, 2023
Renew Biotechnologies’ subsidiary Resonant recently published research in the journal Frontiers in Neurology of a new blood biomarker that promises earlier diagnosis of Alzheimer’s disease (AD). The approach, which centers on the use of cell-free DNA (cfDNA) analyzes differential methylation regions (DMRs) to identify biomarkers that can distinguish neuron-derived cfDNA…
Published on October 25, 2023
Researchers at the Hospital for Sick Children (SickKids), the Ontario Institute for Cancer Research (OICR), and the University Health Network (UHN) have developed a liquid biopsy that an initial study has shown provides earlier detection cancer in individuals with Li-Fraumeni syndrome (LFS) than existing methods. LFS is hereditary disorder that…